Financial Performance - The company's revenue for Q3 2022 was ¥202,676,172.47, representing a decrease of 19.68% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥16,809,430.83, down 57.89% year-on-year[5]. - The basic earnings per share (EPS) was ¥0.03, reflecting a decline of 62.50% compared to the previous year[6]. - Total revenue for the first three quarters of 2022 was CNY 639,857,724.52, a decrease of 18.7% compared to CNY 786,543,185.33 in the same period of 2021[19]. - Net profit for the third quarter of 2022 was CNY 72,240,344.21, a decline of 48.2% from CNY 139,379,458.61 in the same quarter of 2021[20]. - Net profit attributable to the parent company was ¥81,656,073.69, a decrease from ¥145,054,130.16 in the same period last year, representing a decline of approximately 43.6%[21]. - The total comprehensive income attributable to the parent company was ¥79,120,383.83, down from ¥140,234,393.30, reflecting a decrease of about 43.5%[21]. - Operating cash flow for the first three quarters was ¥787,804,291.37, compared to ¥907,386,104.03 in the previous year, indicating a decline of approximately 13.2%[22]. - Basic earnings per share were ¥0.17, down from ¥0.31, reflecting a decline of approximately 45.2%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,308,773,679.24, a decrease of 4.80% from the end of the previous year[6]. - Total assets as of September 30, 2022, amounted to CNY 2,308,773,679.24, a decrease from CNY 2,425,061,985.01 at the end of 2021[16]. - Total liabilities decreased to CNY 973,900,770.08 as of September 30, 2022, compared to CNY 1,050,493,741.79 at the end of 2021[17]. - Current assets totaled CNY 679,361,297.38, down from CNY 829,049,009.21 at the end of 2021, reflecting a decrease of 18.1%[16]. - The company’s total equity as of September 30, 2022, was CNY 1,334,872,909.16, down from CNY 1,374,568,243.22 at the end of 2021[17]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥146,225,545.18, a decrease of 4.10% compared to the previous year[5]. - Net cash flow from operating activities was ¥146,225,545.18, slightly down from ¥152,474,646.59, a decrease of about 4.5%[22]. - Cash flow from investing activities showed a net outflow of ¥117,923,223.20, improving from a net outflow of ¥186,883,429.74 in the previous year[23]. - Cash flow from financing activities resulted in a net outflow of ¥89,299,062.59, compared to a net inflow of ¥73,646,726.04 in the same period last year[23]. - The ending balance of cash and cash equivalents was ¥205,013,631.71, down from ¥253,389,773.42, a decrease of approximately 19%[23]. - The company reported a decrease in cash inflow from investment activities, totaling ¥30,945,318.20, compared to ¥156,423,393.94 in the previous year, indicating a decline of approximately 80.3%[23]. Research and Development - The company reported a significant increase in research and development expenses, totaling CNY 24,253,211.54 in the third quarter of 2022, compared to CNY 22,108,514.40 in the same quarter of 2021[20]. Shareholder Information - The top shareholder, Shuangge Group Co., Ltd., holds 27.78% of the shares, with a significant portion pledged[10]. - The company is awaiting approval from the China Securities Regulatory Commission for a non-public stock issuance, with uncertainty regarding the approval timeline[12]. Government Support - The company received government subsidies amounting to ¥876,137.39 during the reporting period[7]. Tax Information - The company received tax refunds amounting to ¥51,573,137.85, an increase from ¥39,284,894.73 in the previous year, representing a growth of about 31.5%[22].
济民医疗(603222) - 2022 Q3 - 季度财报